Enliven Therapeutics (NASDAQ:ELVN) Director Lori Anne Kunkel Sells 10,000 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Lori Anne Kunkel sold 10,000 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $34.54, for a total value of $345,400.00. Following the completion of the sale, the director owned 51,884 shares of the company’s stock, valued at approximately $1,792,073.36. This trade represents a 16.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics Stock Up 7.4%

Shares of ELVN stock opened at $36.11 on Wednesday. The stock has a 50-day moving average price of $41.27 and a 200 day moving average price of $30.37. The firm has a market cap of $2.20 billion, a price-to-earnings ratio of -21.62 and a beta of 0.29. Enliven Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $48.53.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. Sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ELVN has been the subject of a number of research reports. Mizuho lifted their price objective on Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. The Goldman Sachs Group lifted their price objective on Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. HC Wainwright lifted their price objective on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Finally, Stifel Nicolaus began coverage on Enliven Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $60.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $61.50.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors have recently modified their holdings of the stock. KBC Group NV acquired a new position in shares of Enliven Therapeutics during the 1st quarter worth about $38,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Enliven Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after buying an additional 594 shares during the period. BNP Paribas Financial Markets grew its position in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after buying an additional 930 shares during the period. Los Angeles Capital Management LLC acquired a new position in shares of Enliven Therapeutics during the 4th quarter worth about $83,000. Finally, Quantbot Technologies LP grew its position in shares of Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.